Liver transplantation (LT) was performed for the first time in Chile in 1969, but only since the 1990s has it been systematically performed. Our health system is strongly centralized, which is a severe limitation for the patients who need to be evaluated and subsequently listed. Although proper human and technological resources are available and our results are comparable to international outcomes (overall patient survival at 1, 5, and 10 years of 82%, 70%, and 64%, respectively), we are limited because of a severe scarcity of grafts, which translates into an availability of approximately 7 organs per million persons and a wait-list dropout rate of 40% every year. Thus, our main challenge for the next few years is to improve access to LT among the populations from the extreme regions of the country and overall to improve the availability of grafts by increasing the awareness of physicians in intensive care units and emergency departments, to develop living donor LT programs, to educate the population in order to decrease family refusal, and to reinforce the system of potential donor detection. Although hard work is mandatory for these improvements, none of these tasks seem to be unreachable in the midterm.
The first liver transplantation (LT) in humans performed in Chile occurred in 1969, (1, 2) only a few years after Starzl performed the first transplant in 1963 and shortly preceded by Brazil. (2) The first successful LT was performed by Hepp in 1985 on a patient with hepatocellular carcinoma (HCC) who survived for 2 weeks and died after hepatic artery thrombosis. (3) However, LT remained somewhat scattered in Chile until 1993 when several programs were opened; since then, over 1500 LTs have been performed. (4) Today, many surgeons and hepatologists properly trained in the United States and Europe are devoted to LT and liver diseases. Nonetheless, the geographic characteristics, cultural peculiarities, health system structure, resource availability, and low donation rates represent significant difficulties for the further development of LT programs. (5) In this article, we detail the characteristics, the results, and the challenges of LT programs in Chile.
Structure of Health System in Chile and Its Impact on LT Availability
Approximately 17% of people in Chile have private forprofit health insurance that includes mostly younger, predominantly male, healthy, and high-income persons. On the other hand, approximately 80% of people have public insurance that assumes the care of the older, sicker, and poorest part of the population. (6, 7) Thus, the facts introduce a bias on the system, so among transplanted patients, 27% have private insurance and only 68% have public insurance. Given that LT has not been a priority for any government during the last 2 decades, the development of LT centers has mostly taken place in the private health system. Thus, 7 out of 8 LT programs belong to the private clinics, although most of the recipients have public insurance. (8) Nonetheless, public insurance pays for LT in private clinics. However, there is an insufficient availability of transplant surgeons and hepatologists in the public system, a situation probably caused by a lack of proper conditions, including technological and economic resources that represent a bottleneck for patients with liver diseases who need to be considered as potential candidates for LT.
Distribution of Transplant Centers
Chile is one of the longest countries on Earth (4329 km). This geographical peculiarity represents a severe difficulty in providing access to transplant programs, considering that over 60% of the total population (17,373,831 inhabitants) lives thousands of kilometers away from Chile's capital, Santiago, which is where the most active LT centers are located. (8) In fact, only 1 center is located out of Santiago, approximately 500 km away in the city of Concepción. There is no regulation about where transplant centers must be located nor about how many of them are needed. This situation has a severe impact on patients living in the most extreme regions of the country who need to travel by airplane for several hours to be evaluated by the transplant team.
As a reflection of the unorganized distribution of transplant centers, different teams performed between 3 and 30 LTs out of 103 procedures in 2017, and 2 university centers performed around two-thirds of them. (8, 9) Naturally, this also impacts access to diagnosis and treatment of liver diseases and the development of properly trained teams in the extreme regions of the country. (9) Again, the generation and reinforcement of transplant teams outside of the center of Chile (probably 1 team on each extreme region of the country) is a necessary achievement to pursue.
Donation Rate
Chile has one of lowest donation rates of the Southern Cone (between 5.7 to 10 donors per million population during the last 10 years). (2, 9) Thus, the waiting time for patients with diseases considered as Model for End-Stage Liver Disease (MELD)-Na score exceptions is approximately 18 months. Subsequent health authorities have not made sufficient efforts to generate an efficient system for the detection and procurement of donors. Furthermore, family refusal for organ donation is as high as 50%. Thus, the 12-month dropout rates for liver failure, HCC, and MELD-Na score exceptions are 47.1%, 37.2%, and 26.6%, respectively (Díaz et al., unpublished). For that reason, bridge therapy for HCC is almost always necessary considering that living donor LT is a very infrequent procedure. Initial efforts are being made to increase living donation as a means to mitigate the scarcity of grafts.
Main Indications and Results
The most frequent causes for LT in Chile are decompensated cirrhosis (42.0%), acute liver failure (ALF; 6.6%), HCC (27.3%), and MELD-Na exceptions (24.1%), ie, refractory ascites, hepatopulmonary syndrome, portopulmonary syndrome, polycystic liver disease, neuroendocrine tumors, and so on. Among patients with cirrhosis, the main etiologies are nonalcoholic steatohepatitis (NASH; 29.7%), alcoholic liver disease (17.2%), chronic hepatitis C virus infection (13.6%), autoimmune hepatitis (13.1%), and cholestatic liver diseases (7.4%) (Fig. 1) . (10) Interestingly, among those patients who require enlistment for ALF, the most common etiology is autoimmune hepatitis (43.1%-65.7%) followed by cryptogenic (22.8%-39.7%). (11) Even considering that most patients with liver failure are transplanted with high MELD-Na scores (26.7 ± 6.3; Díaz et al., unpublished) and frequently are very fragile and sarcopenic, (12) 1-, 5-, and 10-year patient survival rates are 82.3%, 70.0%, and 64.0%, respectively. These longterm results are similar to those reported in Europe (Fig. 2) . (13) For those patients with ALF, 1-and 5-year survival are 77.1% and 70.2%, respectively. (11) Interestingly, among patients with cirrhosis, survival is not related to MELD-Na score (Díaz et al., unpublished). We recently published a series of uncommon indications for LT, ie, gastrointestinal stromal tumors (GISTs), hepatoblastoma, polycystic liver disease, Rendu-Osler-Weber syndrome, Niemann-Pick disease, and so on. Globally, overall survival rates after transplant at 1 and 5 years for patients with these conditions were 84.3% and 80.0%, respectively. (14) 
Graft Allocation
Enlistment is allowed for patients up to 70 years old, including immigrants with more than 5 years of residence. We have a very strict normative for organ allocation, employing a severity criterion guided by MELD-Na for chronic liver failure and by King's College Criteria for ALF. Until December 2011, grafts were allocated according to their waiting time. Since then, MELD score was incorporated as a criterion for enlistment. In October 2016, we replaced MELD with MELD-Na. We considered an operational MELD-Na score for patients with exceptional situations for which the real MELD-Na score does not properly reflect the associated mortality or the quality of life. The exceptions are defined by the National Liver Transplant Committee, which assigns an adjusted MELD-Na score for these conditions. This committee includes a member from every LT center plus a representative of the Public Health Institute (Instituto de Salud Pública) and meets once a month. Its decisions are based on the best available evidence and the best judgment of its members when national data are still not available. Every patient listed with exception points is discussed, and the criteria for a score adjustment in exceptions are the same in all centers for LT in Chile. This normative is employed for patient conditions, including but not limited to HCC, refractory ascites, or encephalopathy, hepatopulmonary syndrome, portopulmonary syndrome, polycystic liver disease, and neuroendocrine tumors. Next, some examples are described.
MALIGNANT LIvER TUMORS
As expected, malignant tumors are mostly HCC within the Milan criteria, without vascular or extrahepatic dissemination. We also included patients with HCC beyond the Milan criteria who meet downstaging criteria after locoregional treatment following 3 months of stability according to Yao's criteria. (15) This condition received an initial operational MELD-Na score of 20, which increased 1 point every 2 months.
CHOLESTATIC LIvER dISEASES
In our series, the most common etiologies are primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), and overlap syndrome (PBC/ autoimmune hepatitis). We used the Mayo score because the MELD score does not adequately predict mortality in this group. (16) We used the Mayo score (≥9.6 in PBC and overlap syndrome and ≥3.6 in PSC) for enlistment with an initial operational MELD-Na score of 15. Later, the operational MELD-Na score increased according to a correlation between the Mayo score and a previously defined MELD-Na score. (17) For instance, a patient with PBC and a Mayo score of 10.3 obtained an operational MELD-Na score of 20 because mortality was similar in these cutoff points (28.0% at 12 months).
COMPLICATIONS Of CIRRHOSIS
This condition includes refractory ascites (considered in patients with more than 1 paracentesis per month for at least 6 months), recurrent spontaneous bacterial peritonitis (SBP; receiving 1 extra point for each episode of SBP), and recurrent hepatic encephalopathy (requiring multiple hospitalizations or presenting as chronic invalidating encephalopathy or persistent encephalopathy despite full treatment). In the absence of significant liver failure, these conditions received an initial operational MELD-Na score of 15, which then increased 2 points every 3 months. Patients with
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Overall Survival Years intense itching, which is refractory to medical treatment and can lead to severe impairment of quality of life, can be enlisted (requiring photograph documentation showing excoriations of skin), receiving an initial operational MELD-Na score of 15, which increases 1 point each 3 months.
OTHER CONdITIONS
Other uncommon conditions include hepatopulmonary syndrome, portopulmonary hypertension, and polycystic liver disease (eventually associated with a decreased renal clearance <30 mL/minute, in which case, a simultaneous kidney transplant would be required; severely impaired quality of life; or malnutrition); metabolic diseases also received additional MELD-Na score points.
Future Directions
The treatment of liver diseases and LT remains a challenging field in Chile, and several points should be improved in the short term and midterm:
1. To increase the access to a proper and early treatment of liver diseases improving its prognosis without LT, a greater-than-usual effort should be made in the prevention and treatment of alcohol-related liver disease, NASH, and HCC. 2. Our low donation rate is a significant bottleneck for access to transplantation. We think that there are no structural obstacles to reach a rate of 12-14 donors per million population in the following 5 years. 3. A rational effort for improving the distribution of LT centers across the country could improve the access to transplant teams for patients from the extreme regions of the country. 4. Considering the population of Chile, a serious evaluation should be made of the number of LT teams needed.
In our opinion, the resolution of these issues could significantly improve access to LT by reducing the dramatic gap between the number of liver grafts and the real need and generating higher-volume LT centers.
In conclusion, the technical and human resources to properly perform LT are fully available in Chile, and the obtained longterm results are similar to those of international outcomes. However, the dramatic scarcity of grafts severely limits the availability of LT. Thus, concerted efforts should be employed to generate a robust structure to detect potential donors and support them until organ procurement. To accomplish this, an increased awareness of the importance of donor detection among intensivists and emergency physicians as well as a cultural change in the citizenry are pivotal.
In our opinion, the characteristics, number, and location of transplant centers should be regulated to maximize the expertise of transplant teams and the access of patients living in the most extreme regions of the country. Surgeons and hepatologists across the country must be aware of the chance to enlist properly selected patients.
Thus, although several advances have been made during the last few decades, additional efforts should be made to improve the availability of LT and to reinforce the expertise of the transplant teams, generating high-volume centers.
